

Solid Tumor KRAS Gene Mutations Analysis

This test detects mutations in the KRAS gene from DNA extracted from formalin-fixed, paraffin-embedded (FFPE) specimens. KRAS gene mutations are present in a variety of human cancers and are associated with a poor prognosis.

Testing Method and Background

The gene target exons are enriched by hybrid capture method followed by Next Generation Sequencing (NGS). This method was optimized for use with low quantity of input DNA (50 ng) obtained from formalin-fixed, paraffin-embedded (FFPE) tissues providing high on-target coverage with coverage uniformity above 95% throughout the entire target region. This analysis is performed on genomic DNA isolated from FFPE tumor tissue and does not differentiate between germline and somatic mutations.

KRAS gene mutations are reported in 90% of pancreatic adenocarcinomas, 40% colorectal cancers and about 15 to 30% of non-small cell lung cancers. Mutated RAS proteins have impaired GTPase activity resulting in continual stimulation of cellular proliferation. Normal (wild type) KRAS is necessary for anti-EGFR treatment to work. Lack of response to EGFR inhibitors has been observed in patients harboring a KRAS mutation.

Highlights of Solid Tumor KRAS Gene Mutation Analysis

Targeted Region

KRAS: Exons 2-4

- **Accurate Results from Low-Quality Samples**
Sensitive variant detection with as little as 50 ng of input DNA, and as low as 5% mutant allele frequency, maximizes the results from low input sample types such as formalin fixed, paraffin embedded (FFPE) sections.
- **Wide-ranging Coverage of Variants**
Assessment of single-nucleotide variants (SNVs) and small insertions/deletions, and whole gene deletions and amplifications.

Ordering Information

Get started (non-HFHS): Print a Molecular Solid Tumor requisition form online at www.HenryFord.com/HFCPD

Get started (HFHS): Order through Epic using test "KRAS Mutation" (MOL8018)

Specimen requirements:

A surgical pathologist should confirm the presence of adequate tumor in materials submitted for analysis. Section from archival paraffin material or frozen surgical biopsies should be confirmed to contain >50% tumor by a surgical pathologist. If the submitted material for analysis contains < 50% of tumor, areas of predominant tumor will be microdissected, if possible, to enrich for neoplastic cells.

- Formalin-fixed, paraffin-embedded tissue, preferably no older than 2 years
- 5-6 tissue sections at 5-6 micron thickness (please include H&E slide and a copy of pathology report)
- Cytology slides (cell block with 500+ tumor cells, submit block or 5-6 tissue sections at 5-10 micron thickness depending on cellularity)
- Extracted DNA - from a CLIA-certified Laboratory

Cause for Rejection: Fresh unfixed tissue, paraffin materials that do not contain tumor cells, improperly labeled specimens, archival paraffin material subjected to acid decalcification.

TAT: 5-10 business days (after Prior Authorization obtained)

CPT Codes: 81275, 81276, G0452

Mail test material to:
Henry Ford Center for Precision Diagnostics
Pathology and Laboratory Medicine
Clinic Building, K6, Core Lab, E-655
2799 W. Grand Blvd., Detroit, MI 48202

Contact us: Client Services, Account and Billing Set-up, and connect with a Molecular Pathologist at (313) 916-4DNA (4362)

For more information on Comprehensive Molecular Services, visit our website
www.HenryFord.com/HFCPD

Revision: 2; 12-02-2024